Update Breast Cancer 2019 part 5: diagnostic and therapeutic challenges of new, personalised therapies in patients with advanced breast cancer = Update Mammakarzinom 2019 Teil 5 : diagnostische und therapeutische Herausforderungen neuer personalisierter Therapien bei Patientinnen mit fortgeschrittenem Mammakarzinom

Significant advancements have been made in recent years in advanced breast cancer and nearly all of them have been in the field of targeted therapy. Pertuzumab and trastuzumab-emtansine (T-DM1) have been able to be introduced in HER2-positive breast cancer. Now other anti-HER2 therapies are being de...

Full description

Saved in:

Bibliographic Details
Main Authors:	Welslau, Manfred (Author) , Schütz, Florian (Author) , Wallwiener, Markus (Author) , Schneeweiss, Andreas (Author)
Format:	Article (Journal)
Language:	English
Published:	2019
In:	Geburtshilfe und Frauenheilkunde Year: 2019, Volume: 79, Issue: 10, Pages: 1090-1099
ISSN:	1438-8804
DOI:	10.1055/a-1001-9952
Online Access:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1055/a-1001-9952 Verlag, lizenzpflichtig, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/a-1001-9952
Author Notes:	Manfred Welslau, Andreas D. Hartkopf, Volkmar Müller, Achim Wöckel, Michael P. Lux, Wolfgang Janni, Johannes Ettl, Diana Lüftner, Erik Belleville, Florian Schütz, Peter A. Fasching, Hans-Christian Kolberg, Naiba Nabieva, Friedrich Overkamp, Florin-Andrei Taran, Sara Y. Brucker, Markus Wallwiener, Hans Tesch, Andreas Schneeweiss, Tanja N. Fehm

MARC


LEADER	00000caa a2200000 c 4500
001	1697238521
003	DE-627
005	20220818070726.0
007	cr uuu---uuuuu
008	200505s2019 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1055/a-1001-9952 \|2 doi
035			\|a (DE-627)1697238521
035			\|a (DE-599)KXP1697238521
035			\|a (OCoLC)1341318623
040			\|a DE-627 \|b ger \|c DE-627 \|e rda
041			\|a eng
084			\|a 33 \|2 sdnb
100	1		\|a Welslau, Manfred \|e VerfasserIn \|0 (DE-588)1209579111 \|0 (DE-627)1697239897 \|4 aut
245	1	0	\|a Update Breast Cancer 2019 part 5 \|b diagnostic and therapeutic challenges of new, personalised therapies in patients with advanced breast cancer = Update Mammakarzinom 2019 Teil 5 : diagnostische und therapeutische Herausforderungen neuer personalisierter Therapien bei Patientinnen mit fortgeschrittenem Mammakarzinom \|c Manfred Welslau, Andreas D. Hartkopf, Volkmar Müller, Achim Wöckel, Michael P. Lux, Wolfgang Janni, Johannes Ettl, Diana Lüftner, Erik Belleville, Florian Schütz, Peter A. Fasching, Hans-Christian Kolberg, Naiba Nabieva, Friedrich Overkamp, Florin-Andrei Taran, Sara Y. Brucker, Markus Wallwiener, Hans Tesch, Andreas Schneeweiss, Tanja N. Fehm
246	3	1	\|a Update Mammakarzinom 2019 Teil 5 \|b diagnostische und therapeutische Herausforderungen neuer personalisierter Therapien bei Patientinnen mit fortgeschrittenem Mammakarzinom
264		1	\|c 2019
300			\|a 10
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a Gesehen am 05.05.2020
520			\|a Significant advancements have been made in recent years in advanced breast cancer and nearly all of them have been in the field of targeted therapy. Pertuzumab and trastuzumab-emtansine (T-DM1) have been able to be introduced in HER2-positive breast cancer. Now other anti-HER2 therapies are being developed (e.g. margetuximab, DS-8201a, pyrotinib) which can overcome other resistance mechanisms in the HER2 signalling pathway. In the field of hormone-receptor-positive breast cancer, an mTOR inhibitor and CDK4/6 inhibitors were introduced in the past. Now the introduction of the first PI3K inhibitor is forthcoming and this inhibitor will involve genetic testing of the tumour for a mutation in the PIK3CA gene. There are also significant advancements in triple-negative breast cancer: By combining chemotherapy and immunotherapy, an advantage for overall survival was able to be demonstrated in a subgroup (immune cells PD-L1-positive). The PARP inhibitor therapy for HER2-negative patients with a germ line mutation in BRCA1 or BRCA2 was also associated with an improved overall survival in a subgroup. These promising new study results are summarised in this review.
700	1		\|a Schütz, Florian \|d 1972- \|e VerfasserIn \|0 (DE-588)12303387X \|0 (DE-627)082307229 \|0 (DE-576)293528810 \|4 aut
700	1		\|a Wallwiener, Markus \|d 1980- \|e VerfasserIn \|0 (DE-588)134044827 \|0 (DE-627)692043934 \|0 (DE-576)27468327X \|4 aut
700	1		\|a Schneeweiss, Andreas \|d 1961- \|e VerfasserIn \|0 (DE-588)109972554 \|0 (DE-627)632849630 \|0 (DE-576)327251859 \|4 aut
773	0	8	\|i Enthalten in \|t Geburtshilfe und Frauenheilkunde \|d Stuttgart : Thieme, 1980 \|g 79(2019), 10, Seite 1090-1099 \|h Online-Ressource \|w (DE-627)324451970 \|w (DE-600)2026496-3 \|w (DE-576)279447663 \|x 1438-8804 \|7 nnas \|a Update Breast Cancer 2019 part 5 diagnostic and therapeutic challenges of new, personalised therapies in patients with advanced breast cancer = Update Mammakarzinom 2019 Teil 5 : diagnostische und therapeutische Herausforderungen neuer personalisierter Therapien bei Patientinnen mit fortgeschrittenem Mammakarzinom
773	1	8	\|g volume:79 \|g year:2019 \|g number:10 \|g pages:1090-1099 \|g extent:10 \|a Update Breast Cancer 2019 part 5 diagnostic and therapeutic challenges of new, personalised therapies in patients with advanced breast cancer = Update Mammakarzinom 2019 Teil 5 : diagnostische und therapeutische Herausforderungen neuer personalisierter Therapien bei Patientinnen mit fortgeschrittenem Mammakarzinom
856	4	0	\|u https://doi.org/10.1055/a-1001-9952 \|x Verlag \|x Resolving-System \|z lizenzpflichtig \|3 Volltext
856	4	0	\|u http://www.thieme-connect.de/DOI/DOI?10.1055/a-1001-9952 \|x Verlag \|z lizenzpflichtig \|3 Volltext
951			\|a AR
992			\|a 20200505
993			\|a Article
994			\|a 2019
998			\|g 109972554 \|a Schneeweiss, Andreas \|m 109972554:Schneeweiss, Andreas \|d 910000 \|d 910400 \|e 910000PS109972554 \|e 910400PS109972554 \|k 0/910000/ \|k 1/910000/910400/ \|p 19
998			\|g 134044827 \|a Wallwiener, Markus \|m 134044827:Wallwiener, Markus \|d 910000 \|d 910400 \|e 910000PW134044827 \|e 910400PW134044827 \|k 0/910000/ \|k 1/910000/910400/ \|p 17
998			\|g 12303387X \|a Schütz, Florian \|m 12303387X:Schütz, Florian \|d 910000 \|d 910400 \|d 50000 \|e 910000PS12303387X \|e 910400PS12303387X \|e 50000PS12303387X \|k 0/910000/ \|k 1/910000/910400/ \|k 0/50000/ \|p 10
999			\|a KXP-PPN1697238521 \|e 3659077054
BIB			\|a Y
SER			\|a journal
JSO			\|a {"relHost":[{"id":{"zdb":["2026496-3"],"issn":["1438-8804"],"eki":["324451970"],"doi":["10.1055/s-00000020"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"publisher":"Thieme","dateIssuedKey":"1980","publisherPlace":"Stuttgart ; New York, NY","dateIssuedDisp":"1980-"}],"pubHistory":["Nachgewiesen 40.1980 -"],"part":{"extent":"10","volume":"79","year":"2019","pages":"1090-1099","issue":"10","text":"79(2019), 10, Seite 1090-1099"},"physDesc":[{"extent":"Online-Ressource"}],"disp":"Update Breast Cancer 2019 part 5 diagnostic and therapeutic challenges of new, personalised therapies in patients with advanced breast cancer = Update Mammakarzinom 2019 Teil 5 : diagnostische und therapeutische Herausforderungen neuer personalisierter Therapien bei Patientinnen mit fortgeschrittenem MammakarzinomGeburtshilfe und Frauenheilkunde","titleAlt":[{"title":"GEBFRA"}],"note":["Erscheint monatlich","Gesehen am 08.11.2024"],"recId":"324451970","title":[{"title":"Geburtshilfe und Frauenheilkunde","title_sort":"Geburtshilfe und Frauenheilkunde"}],"language":["ger"]}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"2019"}],"titleTranslated":[{"translated":"Update Mammakarzinom 2019 Teil 5"}],"id":{"eki":["1697238521"],"doi":["10.1055/a-1001-9952"]},"person":[{"role":"aut","roleDisplay":"VerfasserIn","given":"Manfred","family":"Welslau","display":"Welslau, Manfred"},{"given":"Florian","family":"Schütz","display":"Schütz, Florian","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","family":"Wallwiener","given":"Markus","display":"Wallwiener, Markus"},{"roleDisplay":"VerfasserIn","role":"aut","family":"Schneeweiss","given":"Andreas","display":"Schneeweiss, Andreas"}],"name":{"displayForm":["Manfred Welslau, Andreas D. Hartkopf, Volkmar Müller, Achim Wöckel, Michael P. Lux, Wolfgang Janni, Johannes Ettl, Diana Lüftner, Erik Belleville, Florian Schütz, Peter A. Fasching, Hans-Christian Kolberg, Naiba Nabieva, Friedrich Overkamp, Florin-Andrei Taran, Sara Y. Brucker, Markus Wallwiener, Hans Tesch, Andreas Schneeweiss, Tanja N. Fehm"]},"physDesc":[{"extent":"10 S."}],"title":[{"title_sort":"Update Breast Cancer 2019 part 5","subtitle":"diagnostic and therapeutic challenges of new, personalised therapies in patients with advanced breast cancer = Update Mammakarzinom 2019 Teil 5 : diagnostische und therapeutische Herausforderungen neuer personalisierter Therapien bei Patientinnen mit fortgeschrittenem Mammakarzinom","title":"Update Breast Cancer 2019 part 5"}],"language":["eng"],"note":["Gesehen am 05.05.2020"],"recId":"1697238521"}
SRT			\|a WELSLAUMANUPDATEBREA2019

MARC

Similar Items